Genelux Corporation
General ticker "GNLX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $126.1M (TTM average)
Genelux Corporation follows the US Stock Market performance with the rate: 46.2%.
Estimated limits based on current volatility of 6.5%: low 4.54$, high 5.17$
Factors to consider:
- Total employees count: 23 (+53.3%) as of 2023
- Top business risk factors: Insufficient funding, Labor/talent shortage/retention, Acquisition/divestiture risks, Litigation risks
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.37$, 4.66$]
- 2025-12-31 to 2026-12-31 estimated range: [1.40$, 4.64$]
Financial Metrics affecting the GNLX estimates:
- Positive: with PPE of -2.4 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -28.74 <= 0.33
- Positive: -14.38 < Investing cash flow per share per price, % of -11.01
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term GNLX quotes
Long-term GNLX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $11.07MM | $0.17MM | $0.01MM |
| Operating Expenses | $14.08MM | $24.34MM | $31.70MM |
| Operating Income | $-3.01MM | $-24.16MM | $-31.70MM |
| Non-Operating Income | $-1.09MM | $-4.13MM | $1.83MM |
| Interest Expense | $1.41MM | $3.97MM | $0.00MM |
| R&D Expense | $9.08MM | $12.77MM | $19.00MM |
| Income(Loss) | $-4.11MM | $-28.30MM | $-29.87MM |
| Taxes | $1.10MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $-5.21MM | $-28.30MM | $-29.87MM |
| Stockholders Equity | $-35.78MM | $19.47MM | $26.27MM |
| Assets | $5.53MM | $27.89MM | $34.72MM |
| Operating Cash Flow | $-3.57MM | $-20.27MM | $-21.23MM |
| Capital expenditure | $0.05MM | $1.02MM | $0.38MM |
| Investing Cash Flow | $-0.05MM | $-14.72MM | $-8.13MM |
| Financing Cash Flow | $-0.48MM | $44.02MM | $28.51MM |
| Earnings Per Share** | $-0.21 | $-1.16 | $-0.95 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.